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Synergistic growth inhibition and enhancement of cell death by
combination of Melanoma Differentiation Associated gene-7
(MDA-7/IL-24) and cisplatin in ovarian cancer cell lines

Renyan Liu, Adly Yacoub, Paul Dent
Department of Biochemistry and Molecular Biology, Medical College of Virginia at
Virginia Commonwealth University, Richmond, VA

Abstract
Ovarian cancer is the most lethal gynecological malignancy among women. The
current first-line treatments for ovarian cancer are cisplatin, carboplatin and paclitaxel.
However, resistance to these platinum-based drugs occurs in the large majority of
initially responsive tumors, resulting in fully chemoresistant, fatal disease. Therefore,
the resistance to cisplatin therapy has been a critical hurdle in the management of
recurrent ovarian cancer. The mechanisms responsible for cisplatin resistance are not
completely understood. In the search for new therapies to overcome/bypass cisplatin
resistance, melanoma differentiation gene-7 (MDA-7) IL-24, which is a new cytokine,
has anti-cancer efficacy by suppressing cell growth and inducing apoptosis in a broad
range of tumor cells and does not induce any toxicity in normal cells, thus, making it a
potentially effective therapeutic gene for ovarian cancer. The purpose of this study
was to evaluate the potential therapeutic efficacy of MDA-7 to treat ovarian
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carcinoma. Since adenoviral-mediated MDA-7 gene therapy has been shown to be
well tolerated and showed biological activity in clinical studies in the context of other
carcinomas we assessed the anticancer effects of Ad.mda-7 and in combination with
cis-platinum on ovarian cancer cells.

Our results show that the purified recombinant MDA-7 protein, GST-MDA-7, and
Ad.mda7 virus (5) induced growth arresst and apoptosis in ovarian cancer cells.
However, the apoptosis induction was low and directly correlated with infectivity of
Ad.mda-7 virus (5). The use of a modified Ad.mda-7 virus type5, Ad.mda-7 virus
type(5/3), inhanced infectivity and significantly enhanced ovarian cancer cell killing
in human ovarian cancer cell lines in vitro compared to unmodified Ad.mda-7 virus,
Ad.mda-7 virus type5. Also Ad-mda7 synergizes with cis-platinum in vitro and
enhances ovarian cancer cell death. Taken together, these findings demonstrate that
MDA-7 is capable of promoting growth suppression and inducing cell death in
ovarian cancer cells, at least OVCAR cells and support the pharmacological interest of
the combination of MDA-7 and cis-platinum.
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Chapter I: Introduction

In the United States, it has been reported that the second most common gynecological
cancer is ovarian cancer (Greenlee et al., 2000). The low cancer detection rate of
ovarian cancer contributes to its having the worst prognosis of all gynecological
cancers. Usually the first step in treating ovarian cancer in women with stage I and
stage II is optimal surgical debulking or optimal cytoreduction. The need for
chemotherapy after surgery depends on the disease stage. Patients in stage I A and B
usually don’t need further therapy, however, higher risk patients at stage I C and stage
I grade3 need chemotherapy to reduce their risk of relapse. Higher stages require
combination

therapy

including

platinum

drugs,

paclitaxel

and

radiation.

Platinum-based drugs are established in the treatment of cancer, including ovarian,
head and neck, and lung cancer. The oldest and most commonly used platinum-based
drug is cis-diamminedichloroplatinum (cisplatin), (Cersosimo, 1989; Higby et al.,
1974). Cisplatin is the most used chemotherapeutic drug in ovarian-cancer patients
whose cancers were shown to progress after alkylating-agent-based chemotherapy
(Wiltshaw et al., 1979; Neijit et al., 1987). After more than a quarter century of use in
the treatment of ovarian cancer, these platinum drugs are still the cornerstones of both
front-line management and treatment of recurrent disease (Markman et al., 2003).
Cisplatin is activated via hydrolysis, yielding positively charged, very reactive
aquated species that subsequently can form stable DNA-adducts and as a consequence
cause cell death. Common problems associated with the clinical use of cisplatin are
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cumulative toxicities, and the occurrence of inherent or treatment-induced resistant
tumor cell subpopulations limit the therapeutic efficacy of cisplatin (Ozols, 1991).
This resistance can be acquired through chronic drug exposure or it can result from
the intrinsic factors inside the cancer cells (Siddik, 2003). Reducing the extent of
DNA damage can increase resistance and this can occur through changes in drug
accumulation, intracellular thiol levels, and/or DNA adduct repair (Siddik, 2003).
Generally, resistance is multifactorial, in that multiple mechanisms are involved
within the same tumor cell (Eastman et al., 1988; Richon et al., 1987). However, the
exact mechanism for chemoresistance remains poorly understood. One of the
strategies to reduce the systemic toxicity and resistance to platinum is the use of
combination therapy. Cytotoxic drugs are used in combination with cisplatin therapy
to enhance survival but relapse still remain a major problem. Finding new strategies
are of particular significance, one of the candidate to consider is the melanoma
differentiation associated gene-7 (MDA-7), which was originally identified from
terminally differentiated human melanoma cells treated with beta-interferon and the
protein kinase C activator mezerein (Jiang et al, 1995). This gene displayed potent
tumor killing and apoptosis-inducing properties in a wide variety of solid tumors
including melanoma, malignant glioma, fibrosarcoma and carcinomas of the breast,
cervix, colorectal, liver, lung, ovary and prostate. (Fisher et al., 2002; Fisher et al.,
2005; Inoue et al., 2006; Sarkar et el., 2002; Sarkar et al., 2006; Sauane et al., 2003;
Yacoub et al., 2004). Since MDA-7 potent anti-tumor activity in many cancer cells
was established, it was interesting to test its efficacy on ovarian cancer. This study
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aimed to explore its effects on OVCAR ovarian cancer cells. In this study we
demonstrate that MDA-7 reduces proliferation and enhances cisplatin toxicity of
human ovarian cancer.

Chapter II: Background

2.1. Overview of Ovarian Cancer
Ovarian cancer is the leading cause of death among all gynecological malignancies
(Silverberg et al., 1990; Yancik et al., 1993) and the fifth leading cause of cancer death
among women in the United States. About 1 in every 68 women in the United States
will develop ovarian cancer. The American Cancer Society estimates 21,550 new cases
of ovarian caner being diagnosed, and about 14,600 deaths from ovarian cancer in the
United States in 2009 (NCI) booklet 2009 (NIH Publication No. 06-1561). While the
surgical removal of one or both ovaries (oophorecotomy) certainly reduces the
incidence of ovarian cancer, it is only recommended as an option for high-risk patients.
With diagnosis and treatment at early stages of the disease, the 5-year survival rate can
reach 94%. Nearly 70% of ovarian cancers are diagnosed at advanced stage (McNeil,
1995) as a result the 5-year survival rate can be as low as 28% (Beral, 1987). The high
mortality of ovarian cancer is mainly due to its poor diagnosis and its aggressive nature.
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2.2. Overview of the Molecular Genetics of Ovarian Cancer
Approximately 10% of all epithelial ovarian carcinomas are associated with
autosomal dominant genetic predisposition, primarily by inherited mutations in the
BRCA1 or BRCA2 tumor suppressor genes (Boyd 1998). Mutations of these genes
are also seen in some sporadic ovarian cancers. Other genetic features tend to relate to
specific types of ovarian cancer. In women with a known BRCA1 mutation, the
cumulative lifetime risk of developing ovarian cancer has been estimated to be
approximately 50% (95%CI 44.9 to 55.0%) compared with an approximate 1.7%
lifetime risk in the general US population (Brose et al., 2002).The low-grade tumors
are relatively genetically stable and are characterized by mutations in a number of
genes. The most well characterized molecular alterations are sequence mutations in
KRAS, BRAF and ERBB2 oncogenes. Oncogenic mutations in BRAF, KRAS and
ERBB2 result in constitutive activation of the mitogen activated protein kinase
(MAPK) signal transduction pathway which plays a critical role in the transmission of
growth signals into the nucleus (Vogelstein et al., 2004) and contributes to neoplastic
transformation (Singer et al., 2003). The most common molecular genetic alteration in
mucinous borderline tumors and carcinomas (Type I tumors) is point mutation of
KRAS (Mayr et al., 2006). Other mutations such tumor suppressor, PTEN, occurs in
ovarian carcinomas (Saito et al., 2000). The critical role of the genetic changes in
PTEN and KRAS is highlighted by a recent report showing that inactivation of PTEN
and an activating mutation of KRAS are sufficient to induce the development of
ovarian endometrioid carcinoma in a mouse model (Dinulescu et al., 2005). A
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PI3K/Pten pathway has been reported to be sufficient to induce ovarian carcinoma
(Wu et al., 2007). Invasive serous and undifferentiated ovarian carcinomas are
characterized by TP53 mutations and TP53 protein accumulation. Loss of genetic
material from chromosome 17 is also common. The most common molecular genetic
change in Type II tumors was shown to be mutations of TP53 (Salani et al., 2007).
Moreover, mutation of TP53 occurs very early in the genesis of Type II neoplasms. In
fact, mutant TP53 is observed in intraepithelial neoplasia in the fallopian tube fimbria
of BRCA patients. Importantly, TP53 mutations are inherited during cancer evolution
and contribute to the transformed state. As a result, the initiating genetic changes are
retained in both the primary and recurrent tumors. Other genes involved in the
molecular aetiology of ovarian epithelial tumors include, CDKN2A, RB, GATA4,
RNASET2, CSF1R, ECGF1, EGFR, MYC, SRC, PI3K, AKT2, FGF3 and MDM2.

2.3. Ovarian Cancer Classification
Ovarian tumors can be broadly classified into a benign or malignant. Benign ovarian
tumors are also known as of low malignant potential (LMP) according to world
organization classification (FIGO, 1971, and Serov etal., 1973). There are more than 30
different types of ovarian cancer, categorized by the type of cell where they originate.
The three major types of ovarian tumors are epithelial tumors, germ cell tumors and
sex cord-stromal tumors, which are named according to their histogenesis and
directions of differentiation (Scully, 1979). Epithelial tumors are derived from the
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cells on the surface of the ovary. This is the most common form of ovarian cancer and
occurs primarily in adults. They account for about 67% of all ovarian neoplasms and
80-90% of malignant ovarian tumors. Epithelial ovarian tumors are also classified into
subtypes based on the type of epithelial differentiation that is present in the tumor.
The subtype is serous (40 to 70% of all types); endometrioid tumours are the second
most common, (20% to 25% of all cases). Mucinous epithelial tumours are rarer,
comprising 5% to 20% of all cases (Kosary et al., 1994). Serous tumors are the most
common subtype (Scully, 1987). Germ cell ovarian tumors are derived from the egg
producing cells within the body of the ovary. This occurs primarily in children and
teens and is rare by comparison to epithelial ovarian tumors. They are sub-classified
into teratoma, mature cystic teratoma, immature teratomam, monodermal teratoma,
dysgerminoma, yolk sac tumor, embryonal carcinoma, and choriocarcinoma. They
constitute the second largest group of ovarian neoplasms that is about 20% (Scully,
1987). Dysgerminoma is the most common germ cell tumor, accounting for 50% of
all germ cell tumor cases. Yolk sac tumors (also known as endodermal sinus tumors)
are the third most common germ cell tumor (Scully et al., 1998). Less common germ
cell tumors are embryonal carcinoma (Kurman et al., 1976), immature teratoma,
choriocarcinoma, polyembryomas, and mixed germ cell tumors (Scully, 1987). Sex
cord-stromal neoplasms account for about 6% of all ovarian neoplasms. They are
composed of various cell types derived from gonadal stroma and sex cords. Sex cord
stromal tumors include fibrothecomas, juvenile granulosa cell tumors (JGCT),
Sertoli-Leydig cell tumors (SLCT), and unclassified sex cord stromal tumors (Young
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RH. 2005). Granulosa cell tumors and Sertoli-Leydig cell tumors are the most
common. Unlike patients with common epithelial tumors, in which 75% are
considered to be at stage III or IV at diagnosis, patients with these tumors are at stage
I at diagnosis 70% of the time. Also unlike common epithelial tumors, sex
cord-stromal tumors often have more specific symptoms. Granulosa cell tumors are
most common in postmenopausal women and may cause vaginal bleeding and an
elevated level of the tumor marker inhibin in the blood. Sertoli-Leydig cell tumors are
rare. About 33% of these tumors produce signs of virilism (infrequent menstrual
periods, cessation of menstrual periods before menopause, hoarse voice, and
appearance of facial hair).

2.4. Tumor stages
For cancers such as ovarian cancer, correct staging is important as this can impact on
treatment decisions. An international system of staging for ovarian cancer is used,
which identifies the spread of the ovarian cancer at the point of diagnosis. The staging
system is assessed according to the International Federation of Gynaecology and
Obstetrics (FIGO). According to FIGO, at stage 1, the tumor is confined to the
ovary/ovaries. When only one ovary is affected by the tumor, the ovary capsule is
intact; no tumor is detected on the surface of the ovary; and malignant cells are not
detected in ascites or peritoneal washings, the tumor is said to be at stage 1A. When
both ovaries are affected by the tumor, the ovary capsule is intact; no tumor is
detected on the surface of the ovaries; and malignant cells are not detected in ascites
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or peritoneal washings, the tumor is at stage 1B. When the tumor is limited to one or
both ovaries, with either ovary capsule ruptured, the tumor detected on the ovary
surface, or malignant cells detected in the ascites or peritoneal washings, the tumor is
at stage 1C. At stage 2, tumor involves one or both ovaries and has extended into the
pelvis. When the tumor has extended into the uterus and/or the fallopian tubes and
maliganant cells are not found in ascites or peritoneal washings, the tumor is at stage
2A. When the tumor has extended to another organ in the pelvis and malignant cells
are not detected in ascites or peritoneal washings, the tumor is at stage 2B. When the
tumor is defined as 2A or 2B, but the malignant cells are detected in the ascites or
peritoneal wasings, the tumor is at stage 2C. At stage 3, the tumor involves one or
both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis
and/or regional lymph node metastasis. When there is microscopic peritoneal
metastasis beyond the pelvis, the tumor is at stage 3A. When there is microscopic
peritoneal metastasis beyond the pelvis 2 cm or less in greatest size, the tumor is at
stage 3B. When there is microscopic peritoneal metastasis beyond the pelvis 2 cm in
greatest dimension and/or regional lymph nodes metastasis, the tumor is considered to
be at stage 3C.

2. 5. General treatments of ovarian cancer
2.5.1. Treatments for Stage I and Stage II
Treatment for stage 1 and stage 2 ovarian epithelial cancers may include:
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2.5.1.1.Surgery: Surgical debulking procedure is feasible in ovarian carcinoma (Heintz
et al., 1986). It usually includes removal of the uterus (total hysterectomy),
removal of both ovaries and fallopian tubes (bilateral salpingo-oophorectomy),
partial removal of the omentum, the fatty layer that covers and pads organs in
the abdomen (omentectomy), and surgical staging of the lymph nodes and other
tissues in the pelvis and abdomen. Women in Stage I with the lowest-grade
tumors in one ovary may sometimes be treated only with the removal of the
diseased ovary and tube in order to preserve fertility (Benedet et al., 2000;
Vinatier et al., 1996).
2.5.1.2.Chemotherapy: Patients with stage IA or B disease, grade 1 (or sometimes
grade 2), usually do not need further therapy after surgery. However, higher risk
patients (stage IC, stage I/grade 3) are usually treated with platinum-based
chemotherapy to reduce their risk of subsequent relapse (Markman et al.,
2003).
2.5.1.3.Clinical trials with radiation therapy, chemotherapy, or new treatments

2.5.2. Treatment for Stage III and Stage IV Ovarian Cancer

2.5.2.1.Surgery: Removal of the tumor (debulking), total abdominal hysterectomy,
bilateral salpingo-oopherectomy, and omentectomy
2.5.2.2.Chemotherapy: Combination chemotherapy with a platinum-based drug and a
taxane drug delivered intraperitoneally (through the abdominal cavity) (Albets
et al., 1996; Armstrong et al., 2006; Elit et al., 2007; Markman et al., 2001).
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2.5.2.3.Clinical trials of biologic drugs (targeted therapy) following combination
chemotherapy.

2.6. Treatment for Recurrent Ovarian Cancer
If ovarian cancer returns or persists after treatment, chemotherapy is the mainstay of
treatment, although it is not generally curative in the setting of relapsed disease
(Herzog T. J., 2009). Clinical trial options include additional surgical debulking, and
biologic therapy combined with chemotherapy or radiationtherapy. Medically
inoperable patients can be treated with localized radiotherapy or combined
chemoradiation.

2.7. Chemotherapy treatments
2.7.1. Standard Chemotherapy.
The standard initial chemotherapy uses a combination of: A platinum-based drug, such
as carboplatin (Paraplatin) or cisplatin (Platinol). Carboplatin is preferred over cisplatin
in the combination. Carboplatin works as well as cisplatin but is less toxic and can be
administered in a more convenient way (Herzog T. J., 2009); and a taxane, such as
Taxol, paclitaxel (McGuire et al., 1996) or docetaxel (Taxotere). Currently paclitaxel
is the drug most often used as initial therapy in combination with a platinum drug
(Einzig et al., 1994).
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2.7.2. Chemotherapy for Relapsed or Refractory Cancer.
Unfortunately, even in patients who respond, the disease eventually becomes resistant
to the first-line drugs, and the cancer returns. Some ovarian tumors are resistant to
platinum drugs. Once cancer recurs or continues to progress, the patient may be treated
with more cycles of carboplatin and a taxane drug, or a different type of chemotherapy
drug may be used in combination treatment (McGuire et al., 1996). Gemcitabine is
used in combination with carboplatin for women with advanced ovarian cancer that has
relapsed at least 6 months after initial therapy. Other drugs used for recurrent ovarian
cancer include doxorubicin (Adriamycin), and etoposide.

2.8. Platinum based chemotherapy
The platinum complex cisplatin (cis-diamminedichloroplatinum [II]) cis-DDP, first
described as an antineoplastic agent in 1965 by Rosenberg et al., is among the most
frequently used chemotherapeutics, indicated against a broad range of solid tumors,
which primarily were testicular, ovarian and bladder neoplasms (Cersosimo, 1989;
Higby et al., 1974). Recently the spectrum of indications has been expanded including
now endometrium-, cervix-, prostate-carcinomas; osteosarcomas as well as head and
neck tumors (Petsko, 1995). Additionally, this substance has shown its efficacy against
small cell and non-small cell lung cancer (Eberhardt et al., 1998; Havemann, 1982) and
is being used in the therapy of gastrocarcinomas as well (Kath et al., 2000; Konishi et
al., 1998). Cisplatin is administered intravenously in 3-5 courses spread over several
weeks to months. Individual courses are usually 20-40 mg/m2 (Windebank, 1994).
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Concurrently, cisplatin was tested in combination with a variety of different drugs.
Platinum-containing regimens have proven superior to regimens that lacked platinum
compounds (Markman et al., 2003). In a meta-analysis performed on 37 randomized
studies involving 5,667 patients with advanced-stage disease, those patients given
cisplatin-containing combination chemotherapy were compared with those treated
with regimens that did not include cisplatin (Thigpen et al., 1994). Platinum based
chemotherapy was superior to non-platinum based chemotherapy. A trend favored
platinum combinations over single agent platinum. In studies of cisplatinum
containing regimens, several trials have compared cyclophosphamide and cisplatin
(CP) with cisplatin, doxorubicin and cyclophosphamide (PAC) (McGuire et al.,
1996).

2.9. Platinum Mechanism
2.9.1. Antitumor activity of cisplatinum
The anticancer activity of cisplatin is widely attributed to the formation of a cross-link
adduct involving two adjacent guanines in DNA. Cisplatin forms covalent bonds with
nucleophilic sites on guanine present in all DNA. As cisplatin is a bifunctional agent,
it is able to bind to two sites in a DNA strand. This results in the formation of interand intra- chain cross-linkings (Eastman, 1987), which interferes with cellular
transcription and replication (Jordan, 2000). Regulatory mechanisms detect the
abnormal DNA and so activate a chain of responses to correct it. This, ultimately,
causes cell death. The anticancer efficacy of cisplatin is also influenced by the
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efficiency of cisplatin-DNA adduct removal by the cellular repair machinery, with
nucleotide excision repair being a major pathway. The repair of platinum-DNA
crosslinks is retarded when the DNA is bound to the histones in a nucleosome core
particle (Carte et al., 2000; Wang et al., 2003). In 1996 Mello et al., have shown that the
human mismatch-repair protein, hMSH2, also binds specifically to DNA containing
cisplatin adducts and displays selectivity for the DNA adducts of therapeutically active
platinum complexes. These results suggest a role for hMSH2 in mediating cisplatin
toxicity. Various adducts are formed upon interaction of platinum complexes with
nucleotides, but contribution of individual adducts to antitumor activity and toxicity of
platinum complexes still remains to be examined. Warnke et al., 2001 investigated the
formation of adducts following the reaction of cisdiaminedichloroplatinum (II)
(cisplatin) with various DNA nucleotides. One of the important pathway activated after
Cisplatin treatment is the ATR/ATM (ataxiatelangiectasia mutated [ATM] and ATMand Rad3-related [ATR]) pathway (Pabla et al., 2008), Ras signaling, c-Jun N-terminal
kinase (JNK) and extracellular signal-regulated protein kinase (ERK) signaling
pathways. It is suggested that both ERK and JNK cascades activate a common
downstream factor, activator protein-1 (AP-1), which might be required for DNA repair
following cisplatin treatment. AP-1 is composed of activating transcription factor-2
(ATF-2) and c-Jun, which have been shown by chromatin immunoprecipitation assay
to be involved in regulating the expression of many crucial genes after cisplatin
treatment, such as ERCC1, ERCC3, XPA, MSH2, and RAD50; genes that are related to
DNA damage repair. The main mechanism for removing the cisplatin-induced DNA
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cross-linking is nucleotide excision repair (NER). NER involves more than 30 proteins
and is processed in several steps, including damage recognition, incision of a
nucleotide fragment flanking the damaged DNA, resynthesis by using the undamaged
strand as the template, and then ligation of the existing DNA and the newly synthesized
DNA fragment (Dabholkar et al., 1994). In the process, ERCC1 (excision repair
cross-complementing group 1), which forms a heterodimeric complex with XPF
(xeroderma pigmentosum, complementation group F), is involved in 5’ end incision of
the DNA fragment framing the cisplatin-DNA adduct region, and is the rate-limiting
step in the repair system (Dabholkar et al., 1994).

2.9.2. Cisplatinum Resistance

Currently, the precise mechanisms that induce cellular apoptosis is not yet fully
understood, however cisplatin resistance involves multiple factors (Jordan, 2000). As a
summary, cisplatin resistance can be divided into three pharmacological mechanisms:
(i) reduced platinum accumulation, (ii) enhanced platinum detoxification and
metabolism, and (iii) enhanced repair of DNA damage; and one molecular mechanism:
(iv) increased cellular survival signals and decreased apoptotic potential (Jordan,
2000).

2.10. New Approach therapy
The melanoma differentiation associated gene-7 was identified by subtractive
hybridization from a human melanoma cell line, HO-1, from terminally differentiated
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human melanoma cells treated with beta-interferon and the protein kinase C activator
mezerein resulted in cell morphology changes, modifications in gene expression,
alterations in surface antigen expression, and terminal cell differentiation (Fisher et al.,
1985; Guarini et al., 1989, 1992; Jiang and Fisher, 1993; Jiang et al., 1993, 1995). The
MDA-7/IL-24 is localized on human chromosome 1q32–33, a genomic area spanning
195-kb and containing a family of genes associated with the interleukin (IL)-10
family of cytokines (Kotenko et al., 2002; Pestka et al., 2004). Based on its
chromosomal location, structure, and expression profile MDA-7 was confirmed to
have cytokine nature, and therefore was re-designated as interleukin-24 (Caudell et al.
2002).

The mRNA encoding MDA-7/IL-24 is ~2-kb encoding a polypeptide of

~23.8-kDa (Jiang et al., 1995). The MDA-7/IL-24 gene is composed of 7 exons and 6
introns (Huang et al., 2001). Sequence analysis also reveals the presence of a
49-amino acid signal peptide that allows the molecule to be cleaved and secreted.
Sequence analysis of MDA-7/IL-24 reveals 3 putative glycosylation sites at amino
acids 95, 109, and 126 resulting in different forms and molecular sizes of secreted
MDA-7/IL-24. A large body of data demonstrates that IL-24 results in growth
suppression and induction of apoptosis in a broad range of cancer cells (Chada et al.,
2004; Cunningham et al., 2005; Fisher et al., 2003; Fisher, 2005; Gopalkrishnan et al.,
2004; Lebedeva et al., 2005; Sauane et al., 2003; Tong et al., 2005), but not in normal
human cells and its apoptotic effect was independent of classic tumor suppressor
genes, such as p53, Rb and p16 and Bax. A Phase I/II clinical trial in patients with
advanced carcinomas involving intratumoral administration of Ad-IL-24 has
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documented that this gene is safe and well tolerated by patients and a single virus
injection elicits apoptosis in most of the tumor (Chen et al.2003; Saeki et al. 2002;
and Sieger et al.2004).

2.11. Overview of Cell signaling
Currently, chemotherapeutic drugs are widely used to treat cancer. Despite the diverse
primary modes of action of those anti-tumor drugs, most anti-tumor agents utilmately
exert their cytotoxicity by inducing apoptosis. Cancer cells treated in vitro with
different drugs usually die via apoptosis and many studies have shown that apoptosis
is a primary means of drug-induced tumor cell death in vivo (Kaufmann et al., 2000;
Mesner et al., 1997). Recent studies are mainly focused on the signal transduction
pathways and molecular mechanisms that link drug-induced damage to an apoptotic
response. A complex network of survival and death pathways are integrated during
cellular commitment to apoptosis, or the ability to evade apoptosis in response to
damage.

Among

the

pathways

regulating

cell

survival

and

death,

the

best-characterized pathways are those mediated by the mitogen-activated protein
kinase (MAPK) family (Widmann et al., 1999). MAPKs can transduce a variety of
extracellular and intracellular stimuli into alterations in gene expression and cell
function. Three distinct MAPK pathways have been characterized, extracellular
signal-regulated kinase 1 and 2 (ERK1/2), c-Jun N-terminal kinase/stress-activated
protein kinase (JNK/SAPK), and p38. The ERK1/2 pathway is activated by growth
factors through the Ras-Raf-MEK phosphorylation, and by phorbol esters, via
PKC-Raf-MEK pathway and plays a key role in cell proliferation, survival and
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differentiation (Cobb et al., 1999). The stress-activated MAPK pathways JNK/SAPK
(MEK kinase1,3 –MAPK kinase 4,7 [MKK4,7]-JNK1,2,3) and p38 [MAPK kinase
kinase [MAPKKK]-MKK3,6 –p38 a,b,g,d) are activated by environmental and
chemical stress, e.g. UV light, osmotic and oxidative stress, and inflammatory
cytokines (Ahn et al., 1993; Davis et al., 2000; Wilsbacher et al., 1999; Widmann et
al., 1999). The activation of MAPKs requires phosphorylation of conserved tyrosine
and threonine residues by dual specificity MAPK kinases (MEK), which in turn are
activated by phosphorylation of two serine residues by upstream MAPKKKs (Raf).
Phosphorylation of MAPKs results in their translocation to the nucleus, where they
activate transcription factors by phosphorylation (Lenormand et al., 1998; Adachi et
al., 2000). Activity of MAPK kinase (MEK) and MAPKs is inhibited by
de-phosphorylation of the regulatory serine, threonine, and tyrosine residues by
serine/threonine, tyrosine, and dual-specificity phosphatases, respectively (Chu et al.,
1996; Groom et al., 1996). Other less understood ERK isoforms are ERK3, ERK5 and
ERK7. ERK3 isoforms are nearly identical to ERK1 and 2 in the core catalystic
domain (Gonzalez et al., 1992). ERK5 was originally cloned as a homolog of ERK1/2
and as a protein that interact with the orphan MEK, MEK5 (Lee et al., 1995; Zhou et
al., 1995). ERK5 has been implicated in cell cycle control and cell transformation
(English et al., 1999; Kato et al., 1998). ERK7 was shown to be involved in cell
proliferation (Abe et al., 1999). Recent data suggest that MAPKs may mediate
apoptotic signaling by anti-tumor agents. Upon exposure of cancer cells to structurally
and functionally distinct anti-tumor agents, MAPKs activities have been shown to be

19

altered and modulation of MAPK signaling pathways can affect the apoptotic
responses to these drugs.

2.12. Overview of Cell death
Cell death is essential for maintenance of tissue homeostasis as well as embryonic
development in multicellular organisms and plays important roles in cellular stress
responses. The mechanisms for cell death that follows toxic stress are a major focus
of basic research and are also very relevant to translational research in clinical
oncology. Especially, cell death following cancer therapy is of great interest to
researchers. Recently, eight different types of cell death were delineated (Kroemer et
al., 2005) and even as more as 11 pathways were described by some researchers, 10 of
which appear to be programmed (Melino et al., 2005). Generally, there are two main
groups of cell death pathways, apoptotic and non-apoptotic pathways. Apoptotic cell
death refers to classic apoptosis and apoptosis induced by loss of attachment to the
substrate or to other cells (anoikis) (Gilmore, 2005). Non-apoptotic cell death includes
autophagic cell death, necrosis, mitotic cell death (MCD), and caspases-independent
cell death (CICD) triggered by mitochondrial outer membrane permealization
(MOMP). CICD does share some features with classical apoptosis such as MOMP
induction, diffusion of proteins from intermembrane space of mitochondria and the
ensuing DNA fragmentation, however, there is no activation of caspase cascade with
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subsequent cleavage of the plethora of defined intracellular caspase substrates in
CICD, therefore it is classified as a non-apoptotic form of cell death (Okada et al.,
2004).

2. 12.1.

Apoptosis

Apoptosis, the most well-defined type of cell death pathway, is also referred to as type
I programmed cell death. It is a cell death program that occurs in various
physiological and pathological situations (Hengartner, 2000). The term apoptosis is
based on the morphological characteristics of the dying cells, which include
membrane blebbing, cellular shrinkage and reduction of cellular volume,
condensation of chromatin, and fragmentation of the nucleus, all of which eventually
result in fragmentation into membrane bound apoptosis (Kerr et al., 1972; Ziegler et
al., 2004). During apoptosis, the cell membrane becomes asymmetric and
phosphatidylserine (PS) becomes exposed on the cell surface. This PS signals and
leads to the clearance of apoptotic cells by macrophages, thus apoptosis does not
trigger inflammation. Apoptosis is a tightly regulated form of cell death and is
governed by several genes, some of which are mutated or dysfunctionally regulated in
a variety of human tumors (Brown et al., 2005; Philchenkov et al., 2004; Vogelstein et
al., 2004). It can be initiated by two different kinds of signals, intracellular stress
signals and extra-cellular ligands. Two major apoptotic pathways have been described
in eukaryotic cells, extrinsic and intrinsic. Intracellular stress signals, including DNA
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damage, growth factor withdrawal, cytoskeletal damage, oxidative stress or oncogene
activation, endoplasmic reticulum stress, loss of adhesion and others, converge on the
mitochondria and lead to the permeabilization of the mitochondrial outer membrane,
through which the intermembrane space proteins are released into the cytosol. The
release of cytochrome c and other pro-apoptotic proteins propagates the apoptotic
signal. Cytochrome c here serves a cofactor of Apaf-1 to trigger the formation of the
apoptosome and subsequent activation of the initiator and executioner caspases such
as caspase-9 and -3 (Chipuk et al., 2006; Kroemer et el., 2000; Spierings et al., 2005).
In the extrinsic signaling pathway, extracellular ligands such as FasL, TNFa or TRAIL
bind to cell surface receptors, followed by the recruitment of cytosolic adaptor protein
( such as FADD and TRADD), activation of initiator caspases such as caspase-8 and
-10 and subsequent activation of the downstream effector caspases including
caspases-3, -6 and -7 ( Nagata, 1999). However, the extrinsic and intrinsic apoptotic
pathways cross at the level of the mitochondria since caspase-8 can also cleave the
protein Bid into its active form tBid, which is a pro-apoptotic member of the Bcl-2
family of proteins and can induce Bax/Bak-dependent permeabilization of the outer
mitochondrial membrane (MOMP) and release of cytochrome c (Li et al., 1998).
Cytochrome c together with Apaf-1 activates the excecutioner caspase-9 that in turn
activates effector caspases such as caspase-3. Both apoptotic pathways eventually
results in activation of excecutioner caspases, caspase-3, -6 and -7, the major
proteases that degrade the cell. IAPs (inhibitors of apoptosis) can inhibit their acitivty,
while IAPs themselves are inhibited by the proteins SMAC/DIABLO, which can
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promote the activation of caspases and the progression of apoptosis (Du et al., 2000;
Eckelman et al., 2006; Roy et al., 1997; Verhagen et al., 2000). For tumor cells, they
must circumvent apoptosis to survive and proliferate (Hanahan et al., 2000), therefore
tumors usually acquire resistance to apoptosis. For example, loss of function
mutations of p53 tumor suppressor protein is often observed. Because p53 can
promote apoptosis in the context of DNA damage (Vousden et al., 2007), the mutated
p53 is frequently related to a failure to induce apoptosis after cellular stress. Other
examples include loss of functional pro-apoptotic Bax and Bak or over expression of
anti-apoptotic proteins (Kondo et al., 2000; Rampino et al., 1997). What’s more,
modifications in the death receptor pathways can also play a role in apoptosis
resistance such as the reduction or loss of Fas receptor expression in colon carcinomas
(Moller et al., 1994). During tumorigenesis, the genetic and functional alterations that
pro- and anti-apoptotic regulators undergo in cells can significantly impede the
effective excecution of an apoptotic program, resulting in apoptosis resistance, even
when these cells are exposed to certain stress (Johnstone et al., 2002).
In order to kill tumor cells, diverse cytotoxic approaches such as gama-irradiation,
anticancer drugs, suicide genes, or immunotherapy have been employed and have
been shown to induce apoptosis in target cells (Debatin, 1999; Herr et al., 2001;
Kaufmann et al., 2000; Lowe et al., 2000; Solary et al., 2000). The underlying
mechanism for initiation of an apoptosis response in tumor cells upon cytotoxic
therapy may vary for different stimuli and is only partially understood. The damage to
DNA or to other critical molecules and/or subcellular structures induced by cancer

23

therapy seems to be the initiator of cellular stress response in tumor cells (Rich et al.,
2000). Many stress-inducible molecules such as INK, NFkB, ceramide or
MAPK/ERK, may have a significant impact on apoptosis pathways (Davis et al., 2000;
Herr et al., 2001; Mayo et al., 2000).

Most signaling pathways activated by

anticancer drugs eventually result in activation of caspases, the proteases that act as
common death effector molecules in various forms of cell death (Earnshaw et al.,
1999; Degen et al., 2000; Slee et al., 1999; Utz et al., 2000). The ability of anticancer
agents to trigger caspase activation appears to be a critical determinant of sensitivity
or resistance to cytotoxic therapies (Herr et al., 2001; Kaufmann et al., 2000). As a
result, inhibition of caspase activation may be an important factor in chemoresistance
(Herr et al., 2001; Kaufmann et al., 2000). Expression levels of individual caspases
may affect their overall activity, since deficient expression levels of caspases may
impair activation of caspases (Joseph et al., 1999; Janicke et al., 1998; Yang et al.,
2001). For example, there is lack of caspase-3 expression in MCF-7 breast carcinoma
cells due to a frameshift mutation in the caspase-3 gene (Janicke et al., 1998); and
caspase-8 expression was found to be low in a variety of tumor cells derived from
malignant brain tumors, small lung cell carcinoma, and neuroblastoma (Fulda et al.,
2001; Teitz et al., 2000). In contrast, enhanced transcription of caspase genes in
response to cytotoxic treatment may increase expression levels of caspase proteins,
which triggers the pro-apoptotic signaling in cancer therapy (Droin et al., 1998).
Since Bcl-2 family proteins comprise both anti-apoptotic members such as Bcl-2,
Bcl-Xl and Mcl-1; pro-apoptotic molecules such as Bax, Bek, Bad and BH3
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domain-only molecules such as Bid, Bim, and Noxa which link the extrinsic apoptotic
pathway to the intrinsic apoptotic pathway (Antonsson et al., 2000), when Bcl-2
family proteins are mutated or their expression levels are altered, the drug response in
experimental systems can be altered drastically (Minn et al., 1995). For example,
reduced Bax levels cause poor responses to chemotherapy and shorter overall survival
in breast or colorectal carcinoma while enhanced levels of Bax promote the response
to chemotherapy in vivo (Sturm et al., 1999; Sturm et al., 2001). Some recent studies
suggested that there was inhibition of apoptosis by inhibitor of apoptosis proteins
(IAPs) in response to cytotoxic therapy. For instance, cIAP1 or cIAP2 can suppress
apoptosis in vitro following treatment with cisplatin, cytarabine, or TRAIL or after
γ-irradiation (Datta et al., 2000; Suliman et al., 2000).

The transcription factor

NFkB is activated in response to a number of stimuli such as cellular stress and
anticancer drugs and is able to suppress apoptosis by promoting the transcription of
genes for several anti-apoptotic proteins including TRAF1, TRAF 2, cIAP1, cIAP2,
Bcl-Xl, and FLIP, which is thought to confer resistance to cytotoxic therapies (Mayo
et al., 2000). It has been reported that inhibition of NFkB in combination with
chemotherapy enhanced the cytotoxic effect of chemotherapy dramatically when
certain types of anticancer treatments result in induction of NFkB transcriptional
activity, therefore NFkB is likely to be involved in inducible chemoresistance and
inhibition of NFkB may be one of the promising adjuvant approaches to
chemotherapy (Mayo et al., 2000). To conclude, alterations in components of the
apoptotic machinery have an impact on sensitivity of tumor cells toward cytotoxic
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therapy, which suggests a potential way to strengthen the effect of chemotherapy.

2. 12.2.

Autophagy

Cellular homeostasis requires a balance between biosynthetic and catabolic processes.
Eukaryotic cells primarily use to two different mechanisms for large-scale
degradation, the proteasome and autophagy, with autophagy being the one capable of
degrading entire organelles. Autophagy refers to a degrading and recycling process of
cellular constituents that plays a role in the bioenergetic management of starvation as
well as an important physiological role in human health. It usually occurs at basal
levels in most tissues and contributes to the routine turnover of cytoplasmic
components. However, it can also be induced by a change of environmental
conditions such as nutrient depletion. Besides turnover of cellular components,
autophagy is involved in development, differentiation, and tissue remodeling in
various organisms (Levine et al., 2004) and is implicated in certain human diseases as
well. Three main morphologies of programmed cell death (PCD) have been described
in the context of embryonic development (Clarke et al., 2002; Schweichel et al., 1973)
and autophagy is called type II PCD which is characterized by the accumulation of
autophagic vesicles in side the dying cell and is often observed when massive cell
alimination is demanded or when phagocytes do not have easy access to the dying
cells. Autophagy is different from apoptosis in that autophagy uses dying cells’
endogenous lysosomal machinery for most of the dying cells’ degradation whereas
apoptotic cells use phagocytic cell lysosomes for this process. There are three forms

26

of autophagy, macroautophagy, microautophagy, and chaperone-mediated autophagy
(CMA) (Yang et al., 2005; Yorimitsu et al., 2005). These processes differ in the mode
of delivery to lysosomes. Macroautophagy involves the sequestration of unnecessary
and dysfunctional organelles and proteins in a double membrane-bounded vesicle
called autophagosome. In micorautophagy cytosolic components are sequestrated
directly by lysosomes. During CMA, a cytosolic and lysosomal chaperone protein,
hsc70, assists unfolded proteins to translocate into lysosomes. Among the three types,
macroautophagy is the most prevalent form of autophagy (Klionsky et al., 2007;
Levine et al., 2004; Mizushima et al., 2007).

After formation of autophagosomes in

macroautophagy, the autophagosomes undergo a maturation process in which they
fuse with lysosomes to form a single membrane-surrounded vesicle called
autophagolysosome or autolysosome. The outer membrane of the autophagosome
fuses with lysosome (or endosome) membrane while the inner sac enteres the
lysosome where its membrane and its contents are degraded by hydrolyses such as
cathepsins (Eskelinen, 2005; Klionsky et al., 2000; Levine et al., 2004; Mizushima et
al., 2002; Mizushima et al., 1998). The resulting products of degradation are reutilized
to maintain basal macromolecular synthesis or are oxidized inside mitochondria to
maintain bioenergetics. Autophagic processes have been well characterized in yeast
and more than 30 autophagy-related genes (ATG) that encode the proteins excecuting
autophagy have been described in yeast (Klionsky et al., 2003) and in some cases
mammalian orthologs have also been identified (Codogno et al., 2005). A concise
description of the function of autophagy is recycling, reducing waste and yielding
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resources. When damaged organelles and misfolded proteins accumulate in senescent
cells or cells under various stresses such as oxidative stress and infection, autophagic
machinery degrades and reduces this cellular waste. Basal autophagy is constitutively
observed in post-mitotic cells and may play an important role in quality control of
cellular components (Komatsu et al., 2007).

The amino acids and fatty acids

generated from self-digested components by autophagic degradation are used by
tricarboxylic acid (TCA) cycle to produce ATP, which provides energy for various
cellular events. Recent studies suggested a variety of physiological and pathological
roles

of

autophagy

including

development,

aging,

host

defense

system,

neurodegenerative diseases, muscle and cardiac diseases and cancer (Levine et al.,
2008; Mizushima et al., 2008).

The pro-survival function of autophagy has been

very well characterized under circumstances of nutrient starvation when cells can
recycle their macromolecules through autophagy and so try to help cells with
compromised bioenergetics go through stress (Klionsky et al., 2000). Deletion of
autophagy genes increases cell death under nutrient deprivation while in normal
conditions knock-out of autophagic genes does not affect survival (Kuma et al., 2004;
Takeshige et al., 1992). The role of autophagy in maintaining mammalian cellular
homeostasis and survival has been observed at cellular level and the level of entire
organism (Kuma et al., 2004; Komatsu et al., 2005). When denying autophagy to cells
with defects in apoptosis, the cells are not able to tolerate metabolic stress, reducing
cellular fitness and activating a necrotic pathway to cell death (Jin et al., 2007).
Autophagy also occurs to maintain cellular energy homeostasis and bioenergetics
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where there is growth factor deprivation. In this case, even though the cells are
exposed to plenty of nutrients in their extracellular environment, growth factor
withdrawal leads to the loss of their ability to uptake the nutrients (Lum et al., 2005).
This phenomenon has been observed in apoptosis-deficient cells. In normal cells,
serum starvation usually induces apoptosis and it is difficult to see autophagy (Lum et
al., 2005). Though apoptosis-deficient cells under stress in the presence of Atg genes
are able to perform autophagy to recover themselves, they eventually undergo atrophy
and finally die of self-consumption and bioenergetic failure. In apoptosis-competent
cells, when the cells cannot be saved by autophagy, then they undergo apoptosis and
where to go depends on the kind of stimulus (Boya et al., 2005). It has also been
reported that anoxia-reoxygenation induces apoptosis, that the autophagy inhibitor
3-MA increases cell death (Dosenko et al., 2006) and that autophagy plays a
protective role in chronic ischemia (Yan et al., 2006). These results suggest that
autophagy acts as a cell-survival mechanism. However, in some apoptotic-deficient
systems, autophagy seems to be and alternative death mechanism (Debnath et al.,
2005; Gozuacik et al., 2004). A role for autophagy in initiating cell death has been
reported in cells’s response to ER stress, hypoxia, chemotherapeutic agent, toxins and
virus infections (Daido et al., 2004; Talloczy et al., 2002). When apoptosis is blocked
by zVAD, many different cell lines die with autophagic features which can be
prevented by 3-MA (autophagy inhibitor), siRNA of Beclin1 and Atg7 (genes
mediating autophagy), and Wortamannin (autophagy inhibitor) (Yu et al., 2004).
The role of autophagy as a cell death mechanism is mainly dependent on the type of
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cell line and the stress stimulus and might require particular signaling molecules
(Shimizu et al., 2004). When apoptosis fails under certain conditions, cells choose to
die via autophagy. Interestingly, it has been found that even apoptotic-competent cells
can die through autophagy (Guillon-Munos et al., 2006). An overlap between
autophagic and apoptotic pathways has been reported in some studies in which it has
been observed that apoptotic factors such as TRAIL, FADD, ceramide, and the
kinases DAPK and DRP-1 regulate autophagy (Mills et al., 2004; Pyo et al., 2005).
However, the relationship between autophagy and apoptosis is still under debate.
Increasing evidence suggests that autophagy plays a cytoprotective role in cancer cells
under metabolic stress (Amaravadi et al., 2007; Degenhardt et al., 2006; Mathew et al.,
2007; Qadir et al., 2008) and it may contribute to tumor cell survival and tumor
formation, however, the molecular mechanism underlying the acquisition of vigorous
autophagic activity in cancer cells remains a mystery. A recent study, however,
presented that autophagy is also associated with tumor suppression. It showed that
Beclin1, a mammalian ortholog of ATG6, interacted with class III PI3-kinase, Vps34,
and this interaction was crucial for the induction of autophagy and suppression of the
growth of the xenografted breast cancer cell lines (Furuya et al., 2005; Liang et al.,
1999; Zeng et al., 2006;) and Beclin1 was identified as a candidate of tumor
suppressor. During investigations of autophagy in mammalian cells, a couple of
signaling pathways have been revealed to regulate autophagy. The mammalian target
of rapamycin (mTOR) is a key molecule for regulating cancer cell proliferation.
Rapamycin inhibits mTOR function followed by autophagy induction (Lum et al.,
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2005; Ravikumar et al., 2004). Molecules known to suppress mTOR, including PTEN
and TSC, both of which are considered as tumor-suppressor gene products, can induce
autophagy (Arico et al., 2001; Feng et al., 2005). Interestingly, mTOR-activating
molecules such as class I PI3K and Akt, which are frequently activated in various
cancer cells, inhibit autophagy (Lum et al., 2005; Takeuchi et al., 2005). All of these
findings indicate a tumor-suppression role of autophagy. To conclude, both the gain
and loss of autophagy may play crucial roles in tumor formation and growth. When
autophagy is activated, it can supply nutrients to tumor cells under metabolic stress;
when it is inactive, tumor cells that are supposed to die by autophagy would survive.
Recent studies using transplanted autophagy-deficient tumor cells revealed that DNA
damage and inflammation can be caused by the loss of autophagy and therefore
enhance tumorigenesis (Degenhardt et al., 2006).

2.12.3. Necrosis
Necrosis is defined as a type of cell death that lacks the characteristics of apoptosis
and autophagy, and has been considered as an uncontrolled form of cell death. It is
characterized by loss of membrane integrity, vacuolization of the cytoplasm and
cellular swelling. Upon necrosis, inflammatory response can be induced probably
through the release of intracellular components that alert the innate immune system
(Edinger et al., 2004; Festjens et al., 2006; Zitvogel et al., 2004). This brisk
inflammatory response and immune amplification of the damage signal is in sharp
contrast to apoptotic cells that are silently cleared by tissue macrophages. Therefore,
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necrosis was viewed as strictly a pathological form of cell death that is not a
physiologically programmed process. Necrosis is often associated with unwarranted
cell loss due to pathological traumas such as infection or ischemia, however, it can be
triggered by Fas or TNFa ligand via their respective receptors (Vercammen et al.,
1998), which suggests that necrosis may not be such an uncontrolled form of cell
death as initially considered. Despite the significant effects of necorsis under
pathological conditions, the molecular mechanisms underlying necrotic cell death are
poorly understood. Recent research shows that its occurrence and course might be
tightly regulated (Golstein et al., 2006) and that there exists not only accidental
necrosis, but also normal physiological and programmed necrosis (Proskuryakov et al.,
2002; Syntichake et al., 2002). Increasing evidence suggests that, much like apoptosis,
specific genes have evolved to regulate necrotic cell death (Festjens et al., 2006;
Golstein et al., 2007). Genetic studies have identified death receptor adaptors, such
as receptor-interacting protein kinase 1 (RIPK1) and the tumor necrosis factor (TNF)
receptor-associated factor 2 (TRAF2) as essential regulator of death receptor-induced
necrotic cell death (Holler et al., 2000; Lin et al., 2004). Cells deficient in RIPK1 are
protected from necrotic cell death when treated with Fas ligation and caspase
inhibitors or hydrogen peroxide alone (Shen et al., 2004). In a model where L929
mouse fibrosarcoma cell line treated with TNFa was used, cells initiated a complex
multi-step signal transduction pathway in which Fas-associated death domain (FADD)
is recruited to the TNF receptor 1 (TNF-R1) and induced necrosis, possibly through
its death domain (Festjens et al., 2006). The TNFa-induced necrosis here was
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accompanied by a rapid burst of mitochondrial ROS (reactive oxygen species)
production that could be inhibited by rotenone, an inhibitor of the respiratory chain
complex I (Schulze-Osthoff et al., 1993). Furthermore, Bcl-2 could reduce
TNF-induced necrosis, presumably by maintaining mitochondrial integrity (Festjens
et al., 2006). Down-regulation of the expression of RIPK1 prevented the
mitochondrial manifestations of TNFa-treated L929 cells (Festjens et al., 2006).
RIPK1-deficient Jurkat cells are refractory to the propagation of necrosis induced by
the Fas/TNF-R/TRAIL-R pathway (Chan et al., 2003; Holler et al., 2000). In
DNA-damage-induced necrosis, Jun N-terminal kinase seems to be essential as a
downstream effector of RIPK1 for the permeabilization of mitochondrial membranes
(Yu et al., 2006). RIPK1 might also be indispensable for the accumulation of
pro-necrotic ceramides (Thon et al., 2005). Thus RIPK1 may be an important
regulator of necrosis, acting as an upstream signal.

Another mitochondrial matrix

protein, cyclophilin D (CypD), has also been shown to be important in the mediation
of necrosis. Knockout of the gene encoding CypD induces resistance to necrotic cell
death induced by ROS or Ca overload in, for instance, hepatocytes and fibroblasts
(Nakagawa et al., 2005; Schinzel et al., 2005). Caspases might inhibit the necrotic
pathway, meaning that in some circumstances their inhibition might enhance cell
necrosis. For example, following apoptotic stimulus, such as the expression of Bax or
treatment with tumor necrosis factor (TNF) or Fas ligand, cells will die even in the
presence of caspase inhibitors like zVAD-fmk or anti-apoptotic molecules such as
Bcl-XL that prevent caspase activation (Jaattela et al., 2003; Lockshin et al., 2004).
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Under these conditions, cells that would normally die through apoptosis exhibit all the
characteristics of necrosis. Caspase-independent necrotic cell death can be forestalled
by treatment with antioxidants or by eliminating the activity of RIPK1. All these
results suggest that necrosis could be programmed.

2.12.4. Mitotic Cell Death
Another type of cell death, mitotic cell death (MCD), often referred to as mitotic
catastrophe, is caused by aberrant

mitosis that results in the formation of cell with

two or more micronuclei. In mammalian cells and particularly in tumor cells, mitotic
catastrophe is mainly associated with deficiencies in cell cycle checkpoints (Roninson
et al., 2001; Castedo et al., 2004). It is a major form of tumor cell death after
treatments with IR or certain chemotherapeutic agents (Blank et al., 2003; Torres et al.,
1998). MCD features enlarged and multinucleated cells, incomplete nuclear
condensation, chromosome alignment defects, unequal DNA separation or mitosis in
the presence of DNA damage (Eom et al., 2005; Roninson et al., 2001). As the G2/M
checkpoint is responsible for blocking mitosis when there is damaged DNA, altered
expression of proteins involved in this checkpoint is possibly associated with mitotic
catastrophe. For instance, high expression of proteins such as Cdk1 and cyclin B that
promote entry of mitosis or inhibition/knockout of proteins that prevent premature
mitosis including ATR, ATM, Chk2, and Plk can induce MCD (Brown et al., 2000;
Chan et al., 1999; Jin et al., 1998; Niida et al., 2005). Because p53 can induce
G2-suppression in case of DNA damage via the Cdk-inhibitor p21, p53 might be
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involved in preventing MCD (Bunz et al., 1998). Indeed, p53-mediated arm of the
G2/M checkpoint was shown to play an important role in the prevention of MCD in
cells with damaged DNA (Chan et al., 2000; Fei et al., 2003). Besides defects in
G2/M checkpoint, defective mitotic spindle checkpoints have been associated with
MCD. Appropriate spindle functioning depends on proteins involved in the spindle
formation such as Mad and Bub as well as on chromosomal passenger proteins such
as Survivin and Aurora kinases (Lens et al., 2003; Lens et al., 2006). Knockout of
Survivin gene results in disorganized mitotic spindles in early passage cells that
eventually die through a process like MCD (Okada et al., 2004). Upon concomitant
inhibition of apoptosis and impaired spindle checkpoint function, the cells may
proceed through aberrant anaphase to telophase without any sign of cytokinesis,
giving rise to multinucleated cells, most of which become non-viable. However, some
of

the

multinucleated

cells

can

survive

through

interphase

restitution,

endo-reduplication and activation of DNA repair processes such as homologous
recombination (Blank et al., 2007). Cells that survive abnormal mitosis can potentially
divide asymmetrically, giving rise to aneuploid cells which are generally more
tumorigenic. When cells go into mitosis with damaged DNA, they are more likely to
acquire tumorigenic capacity as these cells are genetically unstable. MCD may kill
such cells and therefore prevent tumorigenesis. In a colon cancer xenograft model, a
dominant-negative mutant survivin significantly induced mitotic catastrophe and
apoptosis as well as inhibition of tumor growth (Tu et al., 2005). High expression of
Survivin is often found in tumor cells while rare in normal cells (Duffy et al., 2007).
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All these results suggest a tumor suppressive role of MCD. One way to cancer therapy
is to induce cell death in tumor cells via MCD by direct inhibition of the G2
checkpoint in combination with DNA damage (Ricci et al., 2006).

2.13. Overview of MDA-7
Melanoma differentiation associated gene, MDA-7/IL-24, is a gene that encodes a
24-KD protein (Pestka et al., 2004; Sauane et al., 2003). In normal cells, the
expression of MDA-7 is restricted to cells of immune system and melanocytes (Huang
et al., 2001; Caudell et al., 2002; Wolk et al., 2002). MDA-7/IL-24 expression is
decreased during pathologic progression of melanocytes to melanomas which can be
demonstrated by both RT-PCR (Jiang et al., 1995) and immunohistochemistry
(Ellerhorst et al., 2002). This correlation between the loss of gene expression and
tumor invasion suggests that MDA-7/IL-24 might function as a tumor suppressor
(Ekmekcioglu et al., 2001; Lebedeva et al., 2002; Jiang et al., 1995). Based on the
results obtained using in vitro studies and in in vivo preclinical animal modeling
(Yacoub et al., 2008 a), MDA-7/IL-24 emerged as a promising new and potentially
applicable anti-tumor therapeutic agent, exhibiting direct tumor growth inhibitory
effects as well as ‘bystander anti-tumor’ properties (Lebedeva et al., 2007). Findings
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from a completed phase I dose-escalation trial on 22 advanced cancer patients who
received intratumoral injection of a non-replicating adenovirus vector carrying the
MDA-7/IL-24 transgene (INGN 241) were recently reported (Cunningham et al., 2005;
Fisher et al., 2003; Fisher et al., 2006; Gupta et al., 2006; Lebedeva et al., 2002; Tong
et al., 2005), and confirmed that the clinical activities of INGN 241 (Ad.mda-7)
include apoptotic and anti-tumor activities and systemic immune activation and can
generate both direct tumor growth inhibition and ‘bystander anti-tumor’ effects,
indicating that MDA-7 is an ideal new candidate for ovarian cancer therapy.

2.13.1. The mechanism by which MDA-7 functions
Within the IL-10 family, IL-19, IL-20 and IL-24 exhibit impressive sharing of
receptor complexes; all three are capable of signaling through IL-20R1/IL-20R2, and
both IL-20 and IL-24 can also use IL-22R1/ IL-20R2. However, the biological
activities of these three cytokines appear quite distinct; since only MDA-7/IL-24
induces tumor-specific apoptosis, and this effect can be receptor-independent (Sauane
et al., 2003). The MDA-7/IL-24 protein binds to IL-20 and IL-22 receptor complexes
leading to JAK/STAT activation (Dumoutier et al., 2001; Parrish-Novak et al., 2002;
Wang et al., 2002). However, treatment with tyrosine kinase-specific inhibitors
(Genistein and AG18) or a JAK-selective inhibitor (AG490) does not alter
Ad.mda-7-induced apoptosis in diverse cancer cell lines (Sauane et al., 2003). In
addition, there is no correlation between the pattern of expression of IL-20R1,
IL-20R2, and IL-22R mRNA and susceptibility to Ad.mda-7-induced cell death in
different cell lines. Therefore, signaling events leading to Ad.mda-7-induced
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apoptosis might be tyrosine kinase independent and can be distinguished from
MDA-7/IL-24 cytokine function-related properties mediated by the IL-20/IL-22
receptor complexes that require JAK/STAT kinase activity (Chada et al., 2004;
Sauane et al., 2003; Su et al., 2005). In vitro studies were done to address the
mechanism(s) by which over-expression of MDA-7/IL-24 induces death selectively in
cancer cells. Despite these efforts, the precise pathways of MDA-7/IL-24-induced
apoptosis remain to be clarified. Evidences from earlier studies implied an
involvement of the intrinsic/mitochondrial pathway of apoptosis. Transfection of
breast carcinoma cells with an MDA-7/IL-24 cDNA resulted in pro-apoptotic Bax
up-regulation and subsequent apoptosis induction (Su et al., 1998; Madireddi et al.,
2000). The onset of apoptosis was blocked by anti-apoptotic Bcl-2 over-expression.
Further studies in melanoma, glioblastoma multiforme (Yacoub et al., 2003; Yacoub
et al., 2004; Su et al., 2003), renal carcinoma (Yacoub et al., 2004) and prostate
carcinomas (Lebedeva et al., 2003; Su et al., 2006; Saito et al., 2005) confirmed the
involvement of the Bcl-family of proteins in MDA-7/IL-24-induced apoptosis. In most
tumor cell contexts, over-expression of MDA-7/IL-24 protein leads to the dramatic
down-regulation of anti-apoptotic (Bcl-2 and Bcl-xL) and/or to the up-regulation of
pro-apoptotic (Bax and Bak) members of the Bcl-family. Interestingly, it has been
found that Ad.mda-7 can induce apoptosis in bax-null DU-145 prostate cancer cells
(Lebedeva et al., 2003); therefore, apoptosis can be mediated by a bax-independent
pathway.

Moreover,

over-expression

of anti-apoptotic

Bcl-family

members

differentially protects prostate cancer cells from the MDA-7-induced apoptosis
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(Lebedeva et al., 2003). Bcl-xL over-expression prevents Ad.mda-7-induced
apoptosis in DU-145 and PC-3 prostate carcinoma cells, while Bcl-2 over-expression
protects LNCaP cells from MDA-7/IL-24-induced apoptosis. The reasons for this
disparity are not completely understood and are currently under investigation.
Detailed studies in prostate cancer cells identify reactive oxygen species (ROS) as an
active component in MDA-7/IL-24-induced apoptosis (Fig. 1) (Lebedeva et al., 2003;
Lebedeva et al., 2005; Yacoub et al., 2003). When overexpressed inside a cancer cell
MDA-7/IL-24 protein directly or indirectly affects mitochondria, resulting in
mitochondrial dysfunction and the inner mitochondria membrane potential to drop
thereby leading to ROS production and to apoptotic death. All of the changes
described above are absent after Ad.mda-7 infection of normal prostate epithelial cells.
Antioxidants (Nacetyl-L-cysteine and Tiron) and inhibitors of mitochondrial
permeability

transition

(cyclosporine

A

and

bongkrekic

acid)

inhibit

Ad.mda-7-induced mitochondrial dysfunction and apoptosis in prostate cancer cells.
By contrast, agents facilitating ROS production (arsenic trioxide, NSC656240, and
PK11195) facilitate Ad.mda-7-induced apoptosis. Ectopic expression of Bcl-2 and
Bcl-xL inhibits mitochondrial changes, ROS production, and apoptosis, providing
additional support for a correlation between mitochondrial dysfunction and Ad.mda-7
action. These studies present definitive evidence that changes in mitochondrial
function and ROS production represent key components associated with selective
killing of prostate cancer cells by MDA-7/IL-24. The ability of MDA-7/IL-24 to
produce ROS may prove extremely important for treatment of pancreatic cancer.
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Pancreatic cancer cells are resistant to MDA-7/IL-24-induced apoptosis due to a
diminished capacity to convert MDA-7/IL-24 mRNA into protein (Su et al., 2001).
This translational block can be reversed by combinational treatment with
Ad.mda-7/IL-24 and agents that increase the ROS levels within cells, such as arsenic
trioxide, N-(4-hydroxyphenyl) retinamide, or dithiophene (Lebedeva et al., 2005).
Induction of apoptosis in vitro and suppression of tumorigenesis in vivo in nude mice
are induced in pancreatic cancers independently of their K-ras status upon
combinatorial treatment with Ad.mda-7/IL-24 and a ROS-inducing agent. ROS
inhibitors, such as N-acetyl-cysteine and Tyron, can block this effect. In addition to
modification of mitochondrial function, MDA-7/IL-24 has also been shown to kill
cancer cells by causing endoplasmic reticulum (ER) stress (Gupta et al., 2006; Sauane
et al., 2004; Sauane et al., 2006). ER stress may be caused by misfolded protein
accumulation followed by the activation of a highly conserved unfolded protein
response (UPR). These events lead to apoptosis through the induction of growth
suppression and DNA-damage-inducible (GADD) genes (Berridge et al., 2000;
Berridge MJ, 2002). The hypothesis of a role for MDA-7/IL-24-induced ER stress and
cancer cell apoptosis is supported by the fact that MDA-7/IL-24 induces GADD genes
and further activates p38 MAPK in the context of transformed cells (Gupta et al.,
2006; Sarkar et al., 2002). Previous studies document that signaling events leading to
Ad.mda-7-induced transformed cell apoptosis are tyrosine kinase-independent
(Sauane et al., 2003). These results suggest that MDA-7/IL-24 cancer cell-specific
activity can occur through mechanisms independent of binding to its currently
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recognized cognate receptors and might even occur independent of receptor function.

2.13.2. Bystander effects of MDA-7
An adenovirus vector expressing a nonsecreted version of MDA-7/IL-24 protein was
generated by deletion of its signal peptide (Sauane et al., 2004). This non-secreted
protein was as effective as wild-type secreted MDA-7/IL-24 in inducing apoptosis in
prostate carcinoma cell lines and displayed transformed cell specificity and
localization of MDA-7/ IL-24 in the Golgi/ER compartments. These results indicate
that MDA-7/IL-24-mediated apoptosis can be triggered through a combination of
intracellular as well as secretory mechanisms and could occur efficiently in the
absence of protein secretion. Treatment of susceptible prostate cancer cell lines with
Ad.mda-7 as well as Ad.SP-MDA-7 induces killing to a comparable extent through
ERK1/2-dependent and JAK/STATindependent pathways (Sauane et al., 2004). The
fact that both secreted and non-secreted forms of MDA-7/IL-24 protein have
comparable apoptosis-inducing activity was unanticipated, adding an additional level
of complexity in understanding how this novel molecule works. Localization of
full-length MDA-7/ IL-24 protein in the ER/Golgi compartments is consistent with
the signal peptide hypothesis (Lingappa et al., 1980) and the currently known and
predicted secreted cytokine nature of the protein (Fisher et al., 2003). Because the
signal-peptideless mutant of MDA-7/IL-24 protein does not contain an export signal,
it is predicted to remain in the cytosol. We have, however, confirmed through
confocal immunofluorescence studies that a significant fraction of this protein is able
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to enter the ER and Golgi apparatus and that proteins derived from wild-type and
mutant viruses appear to have overlapping patterns of localization within the cell
(Sauane et al., 2004). It is not possible to rule out cryptic internalization signals that
become active in the absence of the actual signal peptide, as the identity of these
cryptic sites is currently hypothetical. Western blot analyses performed on
proteinderived cytosolic and extracellular fractions of cells infected with both viruses
indicated that only full-length MDA-7/IL-24 was processed and secreted. It is also
possible that adenovirus infection produced relatively large amounts of protein that
even in the absence of a specific targeting sequence possesses the ability to cross
membranes and accumulate in the ER/Golgi because of charge and/or tertiary
structure. However, because localization of MDA-7/IL-24 is similar in both normal
(P69) and cancer (DU-145) cells, differences in cellular localization of this protein
can be excluded as a direct mechanism underlying the differential apoptosis-inducing
activity of MDA-7/ IL-24 toward cancer cells. There are two possible explanations of
differential MDA-7/IL-24-induced killing in tumor and normal cells. One is that
enhanced sensitivity may be due to the ‘activated’ or ‘destabilized’ nature of tumor
compared to normal cells, which enhances cell death after the ER-stress response is
triggered. The other possibility is that MDA-7/IL-24 not only induces the classical
ER-stress response that favors apoptosis, but it also induces additional specific
pathways that cause apoptosis only in transformed cell lines. We demonstrated that
MDA-7/IL-24 localizes to the ER compartment both in normal and cancer cells and is
therefore in a position to induce this pathway irrespective of the transformation status

42

of the cell (Sauane et al., 2004). Current data provide some support for both
hypotheses, however additional studies are required. GADD family gene induction as
well as p38 MAPK activation is induced only in transformed and not in normal cells
(Gupta et al., 2006; Sarkar et al., 2002) indicating that the disparate response might be
due to differential activation, either in strength or in duration of the ER-stress
response. However, this does not rule out the activation of additional pathways,
specifically in cancer cells. In a microarray-based study, MDA-7/IL-24 was shown to
induce expression of ER-stress response genes such as BiP/GRP78, PP2A, HSJ1 and
TRA1 in H1299 lung carcinoma cells (Sieger et al., 2004). Nevertheless, with the
exception of BiP/GRP78, which is selectively up-regulated in cancer cells (Gupta et al.
2006), no comparative data for most of these genes is available contrasting normal
and cancer cells.

2.13.3. Pathways involved in MDA-7 functions
Expanding studies in diverse systems reveal that the signal transduction pathways
mediating MDA-7/IL-24-induced apoptosis are varied and multiple signaling
pathways are activated in different tumor cell lines upon Ad.mda-7 infection or
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treatment with recombinant GST-MDA-7 protein and Ad-MDA7 (Sauane et al.,
2004Yacoub et al., 2003, 2004, and 2008). Experiments in melanoma cell lines
demonstrated that SB203580, a specific inhibitor of p38 MAPK pathway, protects
these cells from Ad-.MDA7 .induced apoptosis. Ad.mda-7 infection resulted in
phosphorylation of p38 MAPK and induction of the GADD family of genes in
melanoma cells, but not in normal melanocytes (Sarkar et al., 2002). In general,
over-expression of each GADD gene from the family in combination (GADD34,
GADD45α, GADD45ß, GADD45γ and GADD153) led to synergistic or cooperative
antiproliferative effects (54). Ad.mda-7 infection resulted in significant induction of
GADD153, GADD45α and GADD34, and a moderate induction of GADD45γ (Sarkar
et al., 2002). Both inhibition of the p38 MAPK pathway (either pharmacologically
with SB203580 or by an adenovirus expressing a dominant negative p38 MAPK) and
inhibition of the GADD family of genes by an antisense approach rescued melanoma
cells from Ad.mda-7- induced apoptosis. Activation of the p38 MAPK pathway
followed by induction of the GADD family of genes also plays a crucial role in
Ad.mda-7-modulated apoptosis in glioblastoma multiforme (Yacoub et al., 2003;
2004), prostate cancer (Gupta et al., 2006; Sauane et al., 2003; Saito et al., 2005), and
breast cancer cells. Paradoxically, p38 MAPK phosphorylation by MDA-7/ IL-24 in
chronic lymphocytic leukemia (CLL)-B-cells and in glioblastoma promoted survival
of these malignant cells (Sainz-Perez et al., 2006; Yacoub et al., 2008). Both
MDA-7/IL-24 mRNA and protein were overexpressed in the CLL B-cells examined,
and p38 MAPK, a downstream MDA-7/IL-24 signaling target, was highly
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phosphorylated in all CLL cells, but not in normal B-cells. Obviously, phospho-p38
MAPK has no pro-apoptotic functions in CLL cells and may instead be required for
survival, as suggested from these studies. Correspondingly, phosphorylation of p38
MAPK following transfection of CLL cells with MDA-7/IL-24 promoted CLL cell
survival (Sainz-Perez et al., 2006). These studies do not exclude the possibility of
MDA-7/IL-24 signaling through a p38 MAPK-independent mechanism; however,
their data suggest a competition between MDA-7/IL-24 and SB203580 (a specific
inhibitor of p38 MAPK) for p38 MAPK activation. In non-small cell lung carcinoma
(NSCLC) cells, Ad.mda-7 induced apoptosis via up-regulation of double stranded
RNA-dependent protein kinase (PKR). Infection with Ad.mda-7 led to the
phosphorylation of PKR and also its downstream targets eIF2α, Tyk2, Stat1, Stat3,
and p38 MAPK (Pataer et al., 2002; Emdad et al., 2006). Ad.mda-7 treatment
activated caspases 3, 8 and 9 and cleavage of Bid and PARP in NSCLC cells. The
activation of PKR appeared to be upstream of caspase activation because pretreatment
with caspase inhibitors failed to prevent PKR phosphorylation. Treatment with a
serine/threonine kinase inhibitor 2-aminopurine blocked Ad.mda-7-induced apoptosis
as well as activation of PKR and eIF2α (Pataer et al., 2002). A recent study by Chada
et al (Chada et al., 2006) reported PKR up-regulation in breast cancer cell lines upon
Ad.mda-7 infection. Further investigation of the interaction between MDA-7/IL-24
and PKR in NSCLC cells suggested a role for posttranslational regulation of PKR by
MDA-7/IL-24 (Pataer et al., 2005). A physical interaction of MDA-7/IL-24 and PKR
was confirmed by immunofluorescence and coimmunoprecipitation studies. In both
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studies (Pataer et al., 2002; Pataer et el., 2005), the authors indicate an inability of
Ad.mda-7 to induce apoptosis in PKR null (-/-) mouse embryonic fibroblasts (MEF),
but not in PKR wild-type MEFs, providing additional proof of PKR involvement in
Ad.mda-7-modulated

apoptosis.

Nevertheless,

this

finding

requires

further

independent confirmation given that Ad.mda-7 does not induce apoptosis in a wide
array of normal human or rodent cells. Activation of p38 MAPK following Ad.mda-7
infection appears to be a common event linking the PKR and p38 MAPK pathways
(Sarkar et al., 2002; Pataer et al., 2002; Emdad et al., 2006). It is possible that in
melanoma cells p38 MAPK activation is downstream of PKR activation, although in
melanoma cells the post-p38 signal transduction changes seem to be more important
in Ad.mda-7-induced apoptosis. Since eIF2α phosphorylation activates the
transcription factor ATF4, which in turn activates GADD153 (Fawcett et al., 1999),
there is a significant level of cross talk between the PKR and the p38 MAPK signal
transduction pathways. Additional studies are required to identify the upstream
molecules within PKR and p38 MAPK pathways involved in Ad.mda-7-induced
apoptosis. The c-Jun NH2-terminal kinase (JNK) pathway is another important
signaling pathway involved in MDA-7/IL-24-induced apoptosis. Infection with
Ad.mda-7 radiosensitizes malignant glioma (Su et el., 2003; Yacoub et al., 2003) and
prostate cancer cells (Su et al., 2006). A combination of Ad.mda-7 and γ-irradiation
activates JNK in glioma and prostate cancer cells, and treatment with a specific JNK
inhibitor, SP600125, prevents apoptosis after the combination treatment (Su et al.,
2006; Yacoub et al., 2003). JNK activation leads to down-regulation of anti-apoptotic
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Bcl-xL and/or Bcl-2 in glioma and prostate carcinoma cells (Yacoub et al., 2004; Su
et al., 2006) and to the up-regulation of pro-apoptotic Bax and Bak proteins in
prostate carcinoma cells (Su et al., 2006). Blocking of JNK phosphorylation with
SP600125 abrogates these changes in the levels of Bcl-family proteins. In NSCLC
cells,

curcumin

(dietary

pigment

that

inhibits

JNK

activation)

prevents

phosphorylation of c-jun and radiosensitization by Ad.mda-7 (Kawabe et al., 2002). A
potential negative regulation of s-catenin and PI3K/Akt signaling pathways, which are
implicated in cell-cell adhesion, cytoskeletal rearrangements, and membrane
trafficking in breast and lung cancer cells, by MDA-7/IL-24 was reported (Mhashilkar
et al., 2003). Using microarray analysis, increased protein expression was evident
from tumor suppressor genes such as E-cadherin, APC, GSK-3ß, and PTEN after
Ad.mda-7 infection. At the same time, expression of proto-oncogenes involved in
s-catenin and PI3K signaling was decreased. Ad.mda-7 treatment led to a
redistribution of cellular s-catenin from the nucleus to the plasma membrane. As a
result, LEF/TCF transactivation was significantly reduced, and E-cadherin-s-catenin
adhesion complex was up-regulated in a tumor cell-specific manner. Furthermore,
Ad.mda-7 infection of breast and lung cancer cells down-regulated the expression of
PI3K pathway members (p85 PI3K, FAK, ILK-1, Akt, and PLC-γ). Experiments did
not indicate if over-expression of s-catenin or activation of the PI3K pathway protects
these cells from Ad.mda-7-induced apoptosis. In conclusion, Ad.mda-7 appears to
negatively regulate both the PI3K and the s-catenin signaling pathways in breast and
lung cancer cells resulting in restoration of apoptosis induction. Moreover, PI3K
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activation has been implicated in chemoresistance and radioresistance in tumor cells;
thus, Ad.mda-7 treatment should serve as a chemo- and radiosensitizer. Ad.mda-7
regulates multiple members of the s-catenin and PI3K pathways that are considerably
redundant

and

simultaneously

produce

antiproliferative,

pro-apoptotic,

and

antimetastatic phenotypes. Although it is not clear where these changes are initiated,
MDA-7/IL-24 appears to act upstream of PI3K, PLC-γ, and PTEN. It is significant
that the s-catenin and PI3K pathways were not altered by MDA-7/IL-24 expression in
normal HUVEC cells. Activation of the Fas-FasL signaling pathway occured in the
human ovarian cancer cell line MDAH 2774 following infection with Ad.mda-7,
where Ad.mda-7 significantly inhibited cell proliferation and induced apoptosis. Early
MDA-7/IL-24-induced activation of the transcription factors c-Jun and activating
transcription factor 2 (ATF2) stimulated the transcription of an immediate
downstream target, the death-inducer Fas ligand (FasL), and its cognate receptor Fas.
The activation of NF-κB and induction of Fas-associated factor 1, FADD, and
caspase-8 were associated with the activation of Fas-FasL (Gopalan et al., 2005).
However, another study by Emdad et al (Emdad et al., 2006) reported p38 MAPK
activation upon adenovirusmediated MDA-7 infection in several ovarian cancer cell
lines. The level of phosphorylated p38 MAPK correlated with the killing effect of
MDA-7/IL-24 in these cells, and SB203580 (selective p38 MAPK inhibitor)
significantly abolished this killing effect. Thus, activation of p38 MAPK presents a
more general effect than induction of the Fas-FasL pathway and might be a key
element in MDA-7/IL-24-induced apoptosis in ovarian carcinoma cell lines as well as
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in other cancer cell lines (Emdad et al., 2006; Gupta et al., 2006; Sarkar et el., 2002;
Yacoub et al., 2003).

Chapter III. Aims of the studies
The purpose of this study is to explore the efficay of MDA-7 on ovarian cancer cells;
to find out the mechanism by which MDA-7 functions in ovarian cancer cells; to try
a new way of delivering MDA-7 to its target and to see the impact on ovarian cancer
cells from its combinational use with cisplatinum.

Chapter IV. Materials& Methods

4.1. Cells lines
SKOIII, OV4, OVCAR cells were obtained from the American Type Culture
Collection. Clones of SKOIII, OV4, OVCAR cells expressing MDA-7 were obtained
by infecting the corresponding cells with Ad.mda-7 (5) or ((5/3)). Western blotting
confirmed expression of MDA-7.

4.2. Reagents
DMEM (Dulbecco’s Modified Eagle’s Medium) and Penicillin-Streptomycin were
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from Gibco (Life technology, New York). Typan blue solution and dimethyl sulfoxide
(DMSO) were all purchased from Sigma Chemical (St. Louis, MO). Phospho-P38
rabbit polyclonal IgG, phospho-JNK rabbit polyclonal IgG, phospho-AKT rabbit
polyclonal IgG, caspase3 mouse monoclonal IgG, and anti-caspase9 mouse
monoclonal IgG were from Cell Signaling (Beverly, MA). PARP (H-250) rabbit
polyclonal IgG, p-PERK (Thr981) rabbit polyclonal IgG, GAPDH (2D4A7) mouse
monoclonal IgG, and p-ERK (E-4) mouse monoclonal IgG were from Santa Cruz
Biotechnology(Santa Cruz, CA). Horseradish peroxidase-conjugated anti-mouse or
anti-rabbit IgG antibody was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA).

4.3. Cell culture
SKOIII, OV4, OVCAR cells were cultured in DMEM supplemented with 5% fetal
bovine serum (FBS, Hyclone, Logan, UT) and 2% penicillin/streptomycin. Cells were
incubated in either 6cm dishes that are used for extraction of proteins for further
western blot analysis or 12-well plates that are used for typan blue assay and all in
humidified atmosphere of 5% CO2 at 37 oC. Since both OV4 and OVCAR cells grow
fast, usually 200,000 cells are plated in a 6cm dish and 10,000 cells are plated in a
well of a 12-well plate. As SKOIII grows much slower than OV4 and OVCAR,
250,000 cells are plated in a 6cm dish and 20,000 cells are plated in a well of a
12-well plate. After 24h of incubation when the cells become attached well to the
plates, they are subjected to treatment with virus or some other drugs such as
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GST-MDA-7 or Cis-platinum.
4.4. Adeno-virus infection
Ad.mda-7 (5) or (5/3) and control adenoviral vectors were used to infect ovarian
cancer cells. The viral titers range from 20moi to 100moi, depending on the cell types
and the experimental design. The cells were incubated with purified virus in 1ml of
DMEM without FBS at 37 oC in a humidified atmosphere of 5% CO2 with gentle
agitation. After 3~4h, fresh DMEM with 10% FBS was added and the cells were
incubated in humidified atmosphere of 5% CO2 at 37 oC at different time course.
4.5. Assessment of Cell Viability
The cells cultured in the 12-well plates were isolated by trypsinization and recovered
by centrifugation. After trypsinization with 300ul of trypsin for some time and cells
could be seen detached from the wells under a microscope, 600ul of
Phosphate-buffered saline (PBS, PH7.4) from Invitrogen was then added into the
wells and all the cells were collected into a 15ml conical tube for centrifugation for
5min at 1400rpm. The supernatant was discarded and pellet kept for typan blue assay.
In terms of the cell number estimated, certain amount of typan blue was added into
the tube and the cell pellet was resuspended. Cells were counted in all four fields of a
hemocytometer.

Cell

viability

was

evaluated

by

assessing

trypan

blue

inclusion/exclusion of isolated cells under light microscopy and scoring the
percentage of cells exhibiting blue staining.
4.6. Preparation of cell extracts and western blot analysis
After treatment for 24h, 48h, or 72h, cells in the 6cm plates were lysed with lysis
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buffer (2Xlaemmli, 120mM Tris HCl pH 6.8, 4% SDS, 20% Glycerol, 10%
beta-mercaptoethanol, 0.001% bromophenol blue). The cell lysate was then boiled on
a heating block at 95 oC for 10min. Protein concentration was determined using a kit
from Bio-rad. Aliquots each of which contains 40ug of sample protein were separated
by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were
blocked with 5% nonfat milk in TBST (5% nonfat milk in 10mM Tris/HCl, 100mM
NaCl, 0.01% Tween-20, pH 7.6) for 2h and then exposed to primary antibodies
overnight at 4 oC. The primary antibodies that we used were Phospho-P38 rabbit
polyclonal IgG, phospho-JNK rabbit polyclonal IgG, phospho-AKT rabbit polyclonal
IgG, caspase3 mouse monoclonal IgG, and anti-caspase9 mouse monoclonal IgG from
Cell

Signaling

(Beverly,

MA)

and

PARP(H-250)

rabbit

polyclonal

IgG,

p-PERK(Thr981) rabbit polyclonal IgG, GAPDH(2D4A7) mouse monoclonal IgG,
and p-ERK(E-4) from Santa Cruz Biotechnology(Santa Cruz, CA) followed by
washing with TBST(3x15min), after which the membranes were incubated with
horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG antibody for 2h,
followed by washing with TBST(3x15min). Proteins imprinted on the membranes
were visualized by enhanced chemiluminescence and quantified by densitometry.
4.7. Statistical analysis
All of the experiments were performed at least three times. Results are expressed as
mean±SEM. A p<0.05 was considered significant.
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Chapter V. Results

5.1. GST-MDA7 effects on OVCAR and SKOVIII cell carcinoma
Previously it has been shown that recombinant GST-MDA-7 and Ad.mda-7 reduced
proliferation and enhanced cell death in diverse cancer cell lines including
non-established human Glioblastoma multiforme (GBM) cells (Cunningham et al.,
2005; Fisher et al., 2005; Gupta et al., 2006; Lebedeva et al., 2002; Tong et al., 2005;
Yacoub et al., 2004), to investigate whether MDA-7 could be used to treat ovarian
cancer cells, we assayed the recombinant GST-MDA-7 on SKOIII and OVCAR
ovarian carcinoma cell lines, the most commonly used ovarian cancer cell lines in
laboratories; and the cell viability as well as growth suppression was evaluated. To
find out the best dose of MDA-7 to treat ovarian carcinoma dose response assays were
performed. Cells were treated with GST-MDA-7 at 0nM, 50nM, 100nM, and 200nM
for 72hours or 96 hours, after which cells were collected and subjected to trypan blue
staining. For OVCAR, at 72h after treatment with GST-MDA-7, the percentages of
live cells are about 100% at 0nM, 80% at 50nM, 63% at 100nM, and 41% at 200nM
while the percentages of cell death are about 10% at 0nM, 10.5% at 50nM, 11% at
100nM, and 17.5% at 200nM(Figure 1 A, B); at 96h, the percentages of live cells are
about 100% at 0nM, 80% at 50nM, 60% at 100nM, and 30% at 200nM while the
percentages of cell death are about 10% at 0nM, 11% at 50nM, 15% at 100nM, and
18% at 200nM(Figure 1 C, D). For SKOVIII, at 72h after treatment with
GST-MDA-7, the percentages of live cells are about 100% at 0nM, 98% at 50nM,
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95% at 100nM, and 90% at 200nM while the percentages of cell death are about 8%
at 0nM, 9% at 50nM, 10% at 100nM, and 16.5% at 200nM(Figure 1 E, F); at 96h, the
percentages of live cells are about 100% at 0nM, 90% at 50nM, 87% at 100nM, and
80% at 200nM while the percentages of cell death are about 8.5% at 0nM, 11% at
50nM, 12.5% at 100nM, and 17.5% at 200nM(Figure 1 G, H). These results showed
that the number of living cells decreased when increasing the concentration of
GST-MDA-7 and the percentage of cell death become higher upon increasing the
concentration of GST-MDA-7 in both OVCAR and SKOVIII, but GST-MDA-7 did
not cause as much cell growth suppression in SKOVIII cells as it did in OVCAR cells
(Figure 1.). GST-MDA-7 caused growth suppression and induced cell death in ovarian
cancer cells, with OVCAR being the most responsive one. Currently the Ad.mda-7
virus is widely used on a variety of cancers, and already in a phase I (Cunningham et
al., 2005; Gupta et al., 2006; Lebedeva et al., 2002; Tong et al., 2005), so it is
important to evaluate the infectivity of MDA-7 viral vectors and their ability to
suppress growth and induce cell death in ovarian cancer cells.
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Figure.1.a. GST-MDA-7 promotes growth suppression and induces cell death in
OVCAR and SKOVIII cells. (A, B). Growth suppression in OVCAR cells after
treatment with GST-MDA-7 for 72h and 96h. (C, D). GST-MDA-7 induces cell death
in OVCAR cells after treatment with GST-MDA-7 for 72h and 96h. Error bars denote
standard error.
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Figure.1.b. GST-MDA-7 promotes growth suppression and induces cell death in
OVCAR and SKOVIII cells. (E, F). Growth suppression in SKOVIII cells after
treatment with GST-MDA-7 for 72h and 96h. (G, H). Cell death in SKOVIII cells
after treatment with GST-MDA-7 for 72h and 96h. Error bars denote standard error.
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5.2. Effects of Ad.mda-7-5 on growth and cell death in ovarian cancer cells
The Ad.mda-7 (5) virus, which is able to infect ovarian cancer cells and leads to the
over-expression of MDA-7 (Gopalan et al., 2007) and which has been under clinical
trials, might have the same effect as GST-MDA-7 did on ovarian cancer cells.
OVCAR is the most sensitive ovarian cancer cells to MDA-7. Therefore in this study
Ad.mda-7 virus (5) was used to infect OVCAR cells. OVCAR cells were treated with
Ad.cmv-5 as negative control and Ad-MDA7-5 at 20moi, 50moi, 80moi, and 150moi.
The cells were harvested 48hours after treatment and subjected to trypan blue assay.
By counting the number of dead and living cells, the percentage of cell death was
obtained. As the concentration of Ad-MDA7 increased, more cell death was observed
(Figure 2). In the control group, there was about 9% cell death. When the cells were
treated at 20moi, the percentage of cell death is about 17%. At 50moi, it is about
17.5%. At 80moi, it is around 24%, while at 150moi, it went up to 34.5% (Figure 2).
In general agreement with other findings in other varieties of cancer cells, Ad.mda-7
(5) was able to infect ovarian cancer cells, OVCAR and enabled the expression of
MDA-7, which thereafter induced cell death in OVCAR. Unfortunately, MDA-7 (5)
here induced the fraction of cell death that was not statistically or clinically significant
at average titration such as 20moi or 50 moi and even at high titration such as 80 moi.
Thus it was necessary to find ways to promote the infection or expression efficiency
of Ad.mda-7, hopefully better results could be obtained than those from Ad.mda-7 (5).
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MDA7-5 48h dose response
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Figure 2. MDA7-5 dose response in OVCAR cells. OVCAR cells were treated with
Ad.cmv-5, and Ad-MDA7-5 at 20moi, 50moi, 80moi, and 150moi for 48h. The
percentage of cell death increased as the dose of Ad-MDA7-5 increased. Error bars
denote standard error.

5.3. Ad.mda-7 ((5/3)) promotes growth suppression and induces cell death in
ovarian cancer cells more effectively than Ad.mda-7 (5)

It has been reported that the modified version of Ad.mda-7 virus, Ad.mda-7 ((5/3)),
which was able to infect tumor cells by bypassing CAR receptors, exhibited higher
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efficiency in infecting ovarian cancer cells than the older version, Ad.mda-7 (5), we
tried this virus to see its effect on our ovarian cancer species, OVCAR. The OVCAR
cells were treated with Ad.mda-7 ((5/3)) at 20moi, 50moi, and 80moi. Like what we
did above with Ad.mda-7 (5), the cells were harvested 48hours after treatment and
subjected to trypan blue assay. By counting the number of dead and living cells, the
percentage of cell death was obtained. As the concentration of Ad-MDA7-(5/3)
increased, more cell death was observed (Figure 3). In the control group, there was
about 8.5% cell death. When the cells were treated at 20moi, the percentage of cell
death is about 32%. At 50moi, it is about 47%. At 80moi, it is around 53% (Figure 3).
When compared with Ad.mda-7 (5), Ad.mda-7 ((5/3)) caused more cell death at
20moi, 50moi and 80moi (Figure 4). The percentage of cell death was much higher
when the OVCAR cells were treated with Ad.mda-7 ((5/3)) than that with Ad.mda-7
(5) at the same concentration, which is in agreement with previous reports that
Ad.mda-7 ((5/3)) is much more effective in infecting ovarian cancer cells than
Ad.mda-7 (5). To increase the cell death caused by Ad.mda-7, Ad.mda-7 ((5/3)) has
been one of the options. Besides this, there should be some other method to achieve
this goal such as the use of Ad.mda-7 in combination with other anti-tumor agents like
the commonly used cisplatinum.
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MDA7-5/3 Dose response
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Figure 3. Ad-MDA7-(5/3) dose response in OVCAR cells. OVCAR cells were
treated with Ad.cmv-(5/3), and Ad-MDA7-(5/3) at 20moi, 50moi, and 80moi for 48h.
The percentage of cell death increased as the dose of Ad-MDA7-(5/3) increased. Error
bars denote standard error.
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MDA7-5 V.S. MDA7-5/3
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Figure 4. Dose response comparison between OVCAR cells treated with
Ad-MDA7-5 and Ad-MDA7-(5/3). The percentage of dead cells was higher in the
groups treated with Ad-MDA7-(5/3) at 20moi, 50moi, and 80moi than those treated
with Ad-MDA7-5 at the same concentration. Error bars denote standard error.

5.4. Cis-platinum shows synergy with MDA-7
Chemotherapeutic drugs such as paclitaxel in combination with cis-platinum has long
been considered as the first-line chemotherapeutic strategy in clinics for patients with
ovarian cancer but recently some types of ovarian cancer have become resistant to
cis-platinum. We would like to see first whether OVCAR is resistant to cis-platinum
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and then whether cis-platinum works synergistically with MDA-7. From the above
studies, Ad.mda-7-5 has been shown to be effective in killing OVCAR ovarian cancer
cells, therefore we used Ad.mda-7-5 in combination with cis-platinum to see whether
they cooperate to cause cell death in OVCAR cells and therefore whether Ad.mda-7-5
could become one of the partners of cis-platinum in the future treatment of ovarian
cancer. The OVCAR cells we used showed dose response to cis-platinum after
treatment for 72 hours. In the control group, there was about 17% cell death. At 1uM
of cis-platinum, the cell death was about 20%. At 2uM, it was 28. At 3uM, it was
around 35%(Figure 5). Cis-platinum was effective in killing OVCAR cells.
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Cis-platinum dose response
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Figure 5. Cis-platinum dose response in OVCAR cells. OVCAR cells were treated
with Cis-platinum at 0uM, 1uM, 2uM and 3uM for 72h. The percentage of cell death
increased as the concentration of Cis-platinum become higher. Error bars denote
standard error.

After infecting OVCAR cells with Ad.mda-7, some groups of cells were treated with
Cis-platinum at 1uM or 2uM. When the cells were treated with Ad.mda-7 at 20moi,
there was about 22% cell death, which was about 8% more than the control. When the
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cells were treated with Ad.mda-7 at 20moi in combination with Cis-platinum at 1uM,
there was about 24% cell death; while the cells were treated with Ad.mda-7 at 20moi
in combination with Cis-platinum at 2uM, there was about 43% cell death. MDA-7
worked synergistically with Cis-platinum in the induction of cell death of OVCAR
cells. So far, MDA-7 had been shown to be a promising anti-tumor agent on ovarian
cancer cells especially OVCAR cells. But what was the mechanism for its activity?

MDA7-5+Cis-Platinum 20moi 72h
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Figure 6. Ad-MDA7-5 and Cis-platinum showed synergistic effect on OVCAR cells
in the induction of cell death. The percentage of cell death was higher in cells treated
with both Ad-MDA7-5 and Cis-platinum for 72hours than treatment with MDA7-5
only. Error bars denote standard error.
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5.5. The molecular mechanism by which MDA-7 functions
In order to clarify the molecular mechanism as well as the signaling pathways through
which MDA-7 increased cell death of OVCAR cells, 20 plates of cells were treated as
the following for 48 hours:
Treatment

Percentage of Cell Death

1. CMV(50moi)

7.0%

2. MDA-7 (5)(50moi)

13.5%

3. CMV+cisplatinum(3uM)

12.5%

4. MDA-7 (5)+cisplatinum

27.0%

5. CMV+dominant-negative caspase-9 (dn9)(50moi)

6.

7.5%

MDA-7 (5)(50moi)+dn9

11.5%

7. CMV+cisplatinum(3uM)+dn9

12.0%

8. MDA-7 (5)+cisplatinum+dn9

16.5%

9. CMV+JNK inhibitor (JIP)(10uM)

7.0%

10. MDA-7 (5)(50moi)+JIP

12.3%

11. CMV+cisplatinum(3uM)+JIP

12.0%

12. MDA-7 (5)+cisplatinum+JIP

19.5%

13. CMV+dominant-negative p38 (dn38)(50moi)

8.0%

14. MDA-7 (5)(50moi)+dn38

12.5%

15. CMV+cisplatinum(3uM)+dn38

12.3%

16. MDA-7 (5)+cisplatinum+dn38

18.6%

17. CMV+Bcl-xL virus (50moi)

6.0%

18. MDA-7 (5)(50moi)+Bcl-xL

9.5%

19. CMV+cisplatinum(3uM)+Bcl-xL

9.6%

20. MDA-7 (5)+cisplatinum+Bcl-xL

17.0%

The percentage of cell death was obtained by doing trypan blue assay. MDA-7 only
increased cell death by 6.5%. cis-platinum increased cell death by 5.5%. Their
combination did it by 20%, which was dramatic increase of cell death and showed
their synergy in this context (Figure 7). When the cells were treated in the same way
but plus dominant-negative caspase-9, the percentage of cell death remained almost
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the same in plate5, but decreased in plate 6 by 2%, in plate 7 by 0.5%, and in plate 8
by 10.5%. It suggests that caspase-9 was favorably involved in cell death (Figure 7).
When the cells were treated in the same way but plus JNK inhibitor, JIP, the
percentage of cell death remained the same in plate 9, but decreased in plate 10 by
1.2%, in plate 11 by 0.5%, and in plate 12 by 7.5%. It suggests that JNK was
favorably involved in cell death (Figure 7). When the cells were treated in the same
way but plus dominant negative p38, the percentage of cell death remained almost the
same in plate 13, but decreased in plate 14 by 1%, in plate 15 by 0.2%, and in plate 16
by 8.4%. It suggests that p38 was favorably involved in cell death (Figure 7). When
the cells were treated in the same way but plus Bcl-xL, the percentage of cell death
decreased in plate 17 by 1%, in plate 18 by 4%, in plate 19 by 2.9%, and in plate 20
by 10%. It suggests that Bcl-xL was favorably involved in cell survival (Figure 7).
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Trypan OVCAR CMV MDA7 Cis dn9, JIP, dn38, and BCLxl
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Figure 7. Cell death of OVCAR treated with CMV (50moi), MDA-7 (5) (50moi),
cis-platinum (3uM), dominant-negative caspase-9, JNK inhibitor, dominant-negative
p38, and Bcl-xL.
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In order to test what genes were involved in OVCAR cells’ response to MDA-7, cell
lysate from cells treated with Ad.cmv or Ad.mda-7 (5) for 0h, 12h, 24h, and 48h were
subjected to western blot analysis. PARP Cleavage was seen only 48h after treatment
with Ad.mda-7 (Figure 8). P-AKT level went down at 12h, 24h and 48h after
treatment with Ad.mda-7 (Figure 8). P-JNK level went up at 12h, 24h and 48h after
treatment with Ad.mda-7 (Figure 8). P-38 level went up only obviously at 24h and
48h after treatment with Ad.mda-7 (Figure 8). P-ERK level went down at 12h, and
24h but went up 48h after treatment with Ad.mda-7 (Figure 8). GAPDH, which was
loading control for the western blot analysis, remained almost the same. These results
suggest that apoptosis occurred in OVCAR at least 48 hours after treatment with
Ad.mda-7; and that JNK, AKT, p38and ERK were involved in OVCAR cells’
response to MDA-7 and their variations facilitated apoptotic cell death of OVCAR.
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Figure 8: Western blot analysis of pro and antiapoptotic genes in OVCAR after
treatment with Ad.cmv or Ad.mda-7.
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Chapter VI. Discussion

Although there is recently tremendous advancement in the treatment of ovarian cancer,
the overall long-term survival rate of this disease has not been improved as expected.
Therefore, here comes the necessity of developing and testing new therapeutic agents
and strategies. Previously it has been reported that the human melanoma
differentiation associated gene-7(MDA-7) has strong anti-tumor activity against
human and murine cancer cells. So, we expect to see whether MDA-7 could become
one of the candidates for ovarian cancer chemotherapy. The above findings show that
MDA-7 can be a candidate for ovarian cancer therapy with its capability of inhibiting
cell growth and inducing cell death.

As an ideal agent for chemotherapy, not only

should it be effective in killing the cancer cells but it also should be readily delivered
to the target of interest. It is already known that it is difficult to administrate a
chemotherapeutic drug that is protein and keep them active upon arrival at their
destination for patients with cancer. In this case, it seems impossible to use
GST-MDA-7 at clinics. Fortunately, viral vectors have currently become one of the
focuses for effectively delivering the chemotherapeutic agents, with Ad.mda-7 virus
being one of them. The recombinant virus Ad.mda-7 has been shown to be effective in
infecting ovarian cancer cells, suggesting a promising way for delivering MDA-7 to
its targets in patients with ovarian cancer. However, the effect of MDA-7 (5) only
effects obviously at high titration of the virus and a long time after infection. This
could be explained by the fact that there are no CAR receptors on OVCAR or
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SKOVIII cell surfaces. It has been reported that CAR serves as a receptor for both
subgroup B coxsackieviruses and adenovirus. Many adenovirus serotypes recognize
CAR with the notable exception of subgroup B viruses (Ads 3 and 7) (Defer et al.
1990; Roelvink et al. 1998). Ad 5’s entry into tumor cells is mediated by CAR.
Possibly because of its capacity of CAR (coxsackieviruse and adenovirus)-dependent
infection of tumor cells and the lack of CAR on OVCAR cell surface, MDA-7 (5) can
induce the fraction of cell death that is not statistically or clinically significant as
suggested by the above findings. The modified version of Ad.mda-7 virus, Ad.mda-7
((5/3)), was reported to be able to infect tumor cells by bypassing CAR receptors,
exhibiting higher efficiency in infecting ovarian cancer cells than the older version,
Ad.mda-7 (5). We tried this virus to see its effect on our ovarian cancer species,
OVCAR. What is more, with this virus, if it is more effective, we can confirm further
the mechanism by which MDA-7 exerts its effect as suggested previously. MDA-7
((5/3)) exhibited apparent effect on the OVCAR cells at relatively low titration
(20moi) of the virus and only 24h after infection. However, there are yet no clinical
trials going on for this type of virus. Future work needs to be done to evaluate its
chemotherapeutic efficacy both in vitro and in vivo. When the Ad.mda-7 virus is
administrated in clinics at high titration like the case in vitro, it may cause side effect
through infecting other irrelevant cells whose cell surfaces are rich in CAR receptors,
which thus compromises the clinical application of MDA-7 (5) virus, so a modified
Ad.mda-7 or some other ways of delivery that can target cancer cells more
specifically are in need.
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Although cis-platinum alone did not exert much effect on OVCAR because of partial
resistance, it is really good news to see that it worked synergistically with MDA-7 (5)
and ((5/3)) in vitro. In vivo studies are necessary both in a short time course as done
in vitro in the present study or in a long time course to see if resistance emerges and to
further clarify the molecular mechanism for it. A following step must be to find ways
of eliminating the trigger of resistance. In this case, once MDA-7 virus is used in
clinics, we could predict what side effects would occur and what could be prepared to
stop them.

In this study, MDA-7 did inhibit cell growth and induced cell death of OVCAR;
nevertheless, the mechanism was unknown. Previous studies suggested that MDA-7
was able to cause apoptosis in cancer cells through multiple pathways (Sauane et al.,
2004). We tested several genes to see whether they were involved in the action of
MDA-7 in OVCAR. From Figure 7 and Figure 8, we could see that Caspase-9, played
important roles in cell death caused by MDA-7, indicating the occurrence of apoptosis
in OVCAR. JNK and p38 were phosphorylated and activated, possibly promoting
apoptosis here. The low level of antiapoptotic gene Akt and the pro-survival effect of
another antiapoptotic gene Bcl-xL after MDA-7 treatment further confirmed that
OVCAR died through apoptosis.
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Chapter VII. Conclusions and implications for further research

This study demonstrated that MDA-7 promoted growth suppression and induced cell
death through apoptosis in ovarian cancer cells. However, apoptosis might not be the
only type of cell death here and it is necessary to test whether autophagy or MCD
occurs in OVCAR after MDA-7 treatment. Although cisplatinum synergized with
MDA-7, it is likely that there is some other antitumor drug that can act in the same
way or even better. It is natural to test MDA-7’s chemotherapeutic effect in
combination with other anti-tumor agents that target different pathways involved in
tumorigenesis for better treatment or even cure of ovarian cancer.
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